GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Biotechnology

More

  • Alexandria CEO: Real estate a long-term play Monday, 13 Jan 2014 | 2:38 PM ET
    Alexandria CEO: Real estate a long-term play

    Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss its firm's success, and how rising yields impact its dividend.

  • Alexandria CEO: Top tenants looking for more space Monday, 13 Jan 2014 | 2:36 PM ET
    Alexandria CEO: Top tenants looking for more space

    Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss real estate demand in the biotech industry.

  • Perrigo CEO: Got to get our name out Monday, 13 Jan 2014 | 2:24 PM ET
    Perrigo CEO: Got to get our name out

    Perrigo CEO Joseph Papa provides insight on the current flu season, and how it plans on getting its name better known.

  • Perrigo CEO: Elan purchase lowers tax rate Monday, 13 Jan 2014 | 2:24 PM ET
    Perrigo CEO: Elan purchase lowers tax rate

    Perrigo CEO Joseph Papa discusses how its new headquarters in Ireland will impact its tax structure, and whether the company will add a dividend.

  • Biogen CEO: More products, company is focused Monday, 13 Jan 2014 | 2:15 PM ET
    Biogen CEO: More products, company is focused

    Biogen Idec CEO George Scangos discusses the busy year ahead for the company, including the EU launch of Tecfidera and when a dividend will be offered.

  • Monsanto wins high court challenge on seed patents Monday, 13 Jan 2014 | 2:06 PM ET
    A protester against Monsanto genetically modified food in New York's Bryant Park.

    The Supreme Court upheld Monsanto's biotech seed patents on Monday, dealing a blow to organic farmers and critics of the company.

  • Roche now world leader in cancer treatment: Pro Friday, 10 Jan 2014 | 2:45 PM ET
    Roche now world leader in cancer treatment: Pro

    The outlook for biotech is "wonderful," explains Sam Isaly, Orbimed Advisors managing partner.

  • Intercept's drug could do billions a year: Analyst Friday, 10 Jan 2014 | 2:42 PM ET
    Intercept's drug could do billions a year: Analyst

    Shares of Intercept Pharmaceuticals are up more than 560 percent this week alone. Akiva Felt, Oppenheimer senior analyst, shares his optimistic view for the company.

  • Singapore growth going to hold up: Pro Wednesday, 1 Jan 2014 | 9:51 PM ET
    Singapore Growth Going To Be OK: Pro

    Daryl Liew, Head Of Portfolio Management of REYL Singapore advises investors to look past short-term volatilities in the country's economy after Q4 GDP data missed expectations

  • Biotech index hits an all-time high Thursday, 21 Nov 2013 | 1:32 PM ET
    Biotech index hits an all-time high

    CNBC's Seema Mody reports the biotech index has hit an all-time high in the Nasdaq.

  • JNJ to pay $2.2 billion in US probe: Feds Monday, 4 Nov 2013 | 1:53 PM ET

    Johnson & Johnson and its subsidiaries were accused of promoting powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients.

  • Biotech stocks bounce up Thursday, 10 Oct 2013 | 3:20 PM ET
    Biotech stocks bounce up

    CNBC's Seema Mody reports on the biggest movers in the Nasdaq including social media stocks like Facebook up 5 percent.

  • NPS Pharma CEO talks life changing treatment

    Francois Nader, NPS Pharmaceuticals president & CEO, discusses its lead product Gattex for "short bowel syndrome," the potential for Netpara and the solid performance of its stock.

  • How to play the biotech boom Monday, 7 Oct 2013 | 2:36 PM ET
    How to play the biotech boom

    Biotech stocks are some of Nasdaq's best performing this year. Joel Sendek, Stifel Nicolaus, looks at names leading the biotech boom.

  • Shutdown not huge for biotech: Pro Tuesday, 1 Oct 2013 | 5:40 PM ET
    Shutdown not huge for biotech: Pro

    How are biotech companies and the FDA impacted by the government shutdown? Yaron Werber of Citi Investment Research, offers insight.

  • Array Biopharma CEO: Developing products ourselves Friday, 27 Sep 2013 | 6:50 PM ET
    Array Biopharma CEO: Developing products ourselves

    Mad Money host Jim Cramer calls Array BioPharma a spec play. The company has 6 trials in phase 3 in progress. Its CEO Ron Squarer discusses its partnerships with big players including Novartis and Celgene.

  • Man fitted with first mind-controlled bionic leg Thursday, 26 Sep 2013 | 11:07 AM ET

    Zac Vawter has been fitted with the first thought-controlled bionic leg, scientists at the Rehabilitation Institute of Chicago reported.

  • Cramer: Forget government shutdown, invest here Thursday, 26 Sep 2013 | 10:14 AM ET

    Want to avoid taking a hit on your portfolio because of troubles in Washington? Cramer found one sector that will be a shelter from the storm.

  • Amgen to buy Onyx for more than $10 billion Monday, 26 Aug 2013 | 7:51 AM ET
    amgen-200.jpg

    Amgen has struck a $10 billion-plus deal to buy Onyx Pharmaceuticals, ending a two-month-long auction for the cancer drugmaker.

  • Amgen close to buying Onyx for $125 per share Saturday, 24 Aug 2013 | 5:32 PM ET
    amgen-200.jpg

    Amgen is close to buying Onyx for $125 per share, or more than $10 billion, in a deal that is expected to be announced as soon as Monday, two people familiar with the matter said on Saturday.